Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act. - 2Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- 3The Best Computer games Ever
- 4Step by step instructions to Lessen Your Gamble of Creating Cellular breakdown in the lungs
- 5Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- From Amateur to Master: My Involvement in Photography
- Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- Careful Living: Embracing the Current Second
- How do my eyes adjust to the dark and how long does it take?
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- 10 Delectable Specialty Mixed drinks
- Is 'Stranger Things' releasing one last episode? The 'Conformity Gate' fan theory explained as speculation mounts.
- 75% of US adults may meet criteria for obesity under new definition, study finds
- In the background: Visiting Notable Film Areas All over the Planet
